TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01285947

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermage
Description: Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermage
Description: Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm

Intervention type: OTHER
Group type: OTHER
Intervention: Needle Application
Description: 30-gauge needle insertion into skin

Intervention type: OTHER
Group type: OTHER
Intervention: Needle Application
Description: 30-gauge needle insertion into skin

Intervention type: DEVICE
Group type: OTHER
Intervention: VBeam Laser
Description: Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20

Intervention type: DEVICE
Group type: OTHER
Intervention: VBeam Laser
Description: Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20

Intervention type: DEVICE
Group type: OTHER
Intervention: Ulthera
Description: Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm

Intervention type: DEVICE
Group type: OTHER
Intervention: Ulthera
Description: Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm
Study: NCT04823416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Left hemicolectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoma
Description: Colostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoma
Description: Colostomy
Study: NCT02151136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24% sucrose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
Study: NCT03555838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
Study: NCT01522820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intranodally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intranodally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intranodally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intranodally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO or PEG
Study: NCT04550507

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful sensory awareness + mindful body awareness check-ins intervention
Description: During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
Study: NCT01522820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO or PEG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO or PEG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO or PEG
Study: NCT04554290

Intervention type: DIAGNOSTIC_TEST
Intervention: temporal artery biopsy
Description: description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
Study: NCT00567463

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
Study: NCT03608228

Intervention type: OTHER
Intervention: Measuring electrical signals from the brain
Description: If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
Study: NCT04701983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Study: NCT04553536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine, Sulfentanil or/and Remifentanil
Description: The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine, Sulfentanil or/and Remifentanil
Description: The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
Study: NCT02793778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CROWN
Description: A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CROWN Placebo
Description: Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
Study: NCT02741193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Magstim Rapid2,
Description: Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability.
Study: NCT01640535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast + Levocetirizine
Description: Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
Study: NCT04057794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lab Assay for seven genetic variants for Parkinson's Disease
Description: Counseling provided to participant by site clinician/physician/genetic counselor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lab Assay for seven genetic variants for Parkinson's Disease
Description: Counseling provided to participant by centralized genetic counseling group at Indiana University.
Study: NCT02129881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous regulatory T Cell Product
Description: Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
Study: NCT00725231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Study: NCT03555838

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
Study: NCT00725231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Study: NCT00641940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls in Transition (GT) program
Description: In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
Study: NCT01045265

Intervention type: OTHER
Intervention: Seminal plasma pharmacokinetics
Description: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
Study: NCT00641940

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants in the waitlist control group will complete the GT program during the third year of the study.
Study: NCT01689506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte
Description: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Serum Albumin
Description: 5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
Study: NCT03778229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: osimertinib (80 mg oral OD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: savolitinib
Description: savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: savolitinib
Description: savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to osimertinib (oral OD)
Study: NCT06209957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local corticosteroid injection
Description: Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich Plasma Local injection
Description: Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
Study: NCT02977091

Intervention type: OTHER
Intervention: change in fitness level
Description: fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness

Intervention type: OTHER
Intervention: change in fitness level
Description: fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
Study: NCT02605694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
Study: NCT04352127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
Study: NCT02053246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
Study: NCT01948310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
Study: NCT04057963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus Functional Inspiratory Muscle Training Group
Description: functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy Program
Description: conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
Study: NCT02951923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum vs. soy during rugby training

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy
Study: NCT02903511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Monitoring of safety and tolerability
Study: NCT03198923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer and natural killer T cell
Description: The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
Study: NCT02072096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Administered orally
Study: NCT02903511

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monitoring of safety and tolerability
Study: NCT01644045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation for the EMS in acute respiratory emergencies
Study: NCT01924715

Intervention type: BEHAVIORAL
Intervention: ISTDP
Description: An emotion focused brief psychotherapy format.
Study: NCT03537690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEOX-based Polymer Encapsulated Paclitaxel FID-007
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT01542372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication augmentation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study: NCT02273115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Foley catheter
Study: NCT02605694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)
Study: NCT02725177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection -Treatment Extension
Description: 24 open label extension permitted in subjects who respond to treatment
Study: NCT03044665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin plus ezetimibe
Description: Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
Study: NCT00385086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF blocker
Description: Treatment with TNF-alpha blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo
Study: NCT04741243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock wave
Description: Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock wave
Description: Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
Study: NCT01972425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker-based diagnostic
Description: The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
Study: NCT01296386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC84
Description: IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC84
Description: IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC84
Description: IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC84
Description: IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
Study: NCT01948310

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)